This invention provides a combination of a first vaccine comprising a porcine circovirus type 2 (PCV2) antigen and a Mycoplasma hyopneumoniae ( M. hyo ) culture supernatant and a second vaccine comprising a porcine reproductive and respiratory syndrome (PRRS) virus antigen, for treating an animal against an infection with PCV2, an infection with M. hyo , and an infection with PRRS virus, wherein the M. hyo culture supernatant has been separated from insoluble cellular material and is substantially free of both IgG and immunocomplexes comprised of antigen bound to immunoglobulin.
1. A combination of a first vaccine comprising a porcine circovirus type 2 (PCV2) antigen and a Mycoplasma hyopneumoniae ( M.hyo ) culture supernatant and a second vaccine comprising a porcine reproductive and respiratory syndrome (PRRS) virus antigen, for treating an animal against an infection with PCV2, an infection with M.hyo , and an infection with PRRS virus, wherein the M.hyo culture supernatant has been separated from insoluble cellular material and is substantially free of both IgG and immunocomplexes comprised of antigen bound to immunoglobulin.
2. The combination of claim 1 , wherein the M.hyo culture supernatant has been treated with protein-A or protein-G.
3. The combination of claim 1 , wherein the first vaccine is in the form of a ready-to-use liquid composition.
4. The combination of claim 1 , wherein the M.hyo culture supernatant comprises inactivated M.hyo antigen.
5. The combination of claim 1 , wherein the PCV2 antigen is in the form of a chimeric type-1-type 2 circovirus, said chimeric virus comprising an inactivated recombinant porcine circovirus type 1 expressing the porcine circovirus type 2 ORF2 protein.
6. The combination of claim 1 , wherein the PCV2 antigen is in the form of a recombinant ORF2 protein.
7. The combination of claim 6 , wherein the recombinant ORF2 protein is expressed from a baculovirus vector.
8. The combination of claim 1 , wherein the PRRS virus antigen is in the form of a genetically modified live PRRS virus.
9. The combination of claim 8 , wherein the genetically modified live PRRS virus is in a lyophilized state.
10. The combination of claim 1 , wherein the first vaccine or second vaccine further comprises at least one additional antigen that is protective against a microorganism that can cause disease in pigs.
11. The combination of claim 10 , wherein the microorganism comprises bacteria, viruses, or protozoans.
12. The combination of claim 11 , wherein the microorganism is selected from the group consisting of Lawsonia intracellularis, Haemophilus parasuis, Pasteurella multocida, Streptococcum suis, Staphylococcus hyicus, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Salmonella choleraesuis, Salmonella enteritidis, Erysipelothrix rhusiopathiae, Mycoplasma hyorhinis, Mycoplasma hyosynoviae , leptospira bacteria, swine influenza virus (SIV), Escherichia coli antigen, Brachyspira hyodysenteriae , porcine respiratory coronavirus, Porcine Epidemic Diarrhea (PED) virus, rotavirus, Porcine enteroviruses, Encephalomyocarditis virus, a pathogen causative of Aujesky's Disease, Classical Swine fever (CSF) virus, a pathogen causative of Swine Transmissible Gastroenteritis, and combinations thereof.
13. The combination of claim 10 , wherein the first vaccine comprises an inactivated Lawsonia intracellularis antigen.
14. The combination of claim 1 , wherein the first vaccine further comprises an adjuvant.
15. The combination of claim 14 , wherein the adjuvant is selected from the group consisting of an oil-in-water adjuvant, a polymer and water adjuvant, a water-in-oil adjuvant, an aluminum hydroxide adjuvant, a vitamin E adjuvant and combinations thereof.
16. The combination of claim 1 , wherein at least the first vaccine further comprises a pharmaceutically acceptable carrier.
17. The combination of claim 10 , wherein the first vaccine further comprises an adjuvant.
18. The combination of claim 17 , wherein the adjuvant is selected from the group consisting of an oil-in-water adjuvant, a polymer and water adjuvant, a water-in-oil adjuvant, an aluminum hydroxide adjuvant, a vitamin E adjuvant and combinations thereof.
19. The combination of claim 10 , wherein at least the first vaccine further comprises a pharmaceutically acceptable carrier.
20. A method of treating an animal against an infection with PCV2, an infection with M.hyo , and an infection with PRRS virus by separate administration of a first vaccine comprising a porcine circovirus type 2 (PCV2) antigen and a Mycoplasma hyopneumoniae ( M.hyo ) culture supernatant, with a second vaccine comprising a porcine reproductive and respiratory syndrome (PRRS) virus antigen.
21. The method of claim 20 , wherein the first vaccine and the second vaccine are co-administered to the animal.
22. The method of claim 20 , wherein the first vaccine and the second vaccine are sequentially administered to the animal.
23. The method of claim 20 , wherein the first vaccine and the second vaccine are administered by a single dose or multiple doses.
24. The method of claim 20 , wherein the first vaccine and the second vaccine are administered by a single dose.
25. The method of claim 20 , wherein the first vaccine and the second vaccine are administered to pigs at 3 weeks of age or older.
26. The method of claim 20 , wherein the first vaccine and the second vaccine are administered intramuscularly, intradermally, transdermally, or subcutaneously.
27. The method of claim 20 , wherein the first vaccine and the second vaccine are administered to pigs having maternally derived antibodies against M.hyo and at least one other microorganism that can cause disease in pigs.
28. The method of claim 27 , wherein the first vaccine and the second vaccine are administered to pigs having maternally derived antibodies against PCV2.